XNYS
BAX
Market cap12bUSD
Oct 08, Last price
23.90USD
1D
-0.29%
1Q
5.66%
Jan 2017
-46.10%
Name
Baxter International Inc.
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Baxter International Inc. is a global healthcare company that develops and supplies a broad spectrum of medical products and services through its various subsidiaries. The company's offerings encompass vital areas such as kidney care, including peritoneal and hemodialysis solutions, along with related therapies and services. It provides essential intravenous (IV) solutions, infusion pumps, administration sets, and drug reconstitution devices. Additionally, Baxter supports hospital pharmacies with premixed and oncology drug formulations, inhaled anesthetics, critical care products, and compounding services. For surgical procedures, Baxter manufactures biological products and medical devices designed to facilitate hemostasis, tissue sealing, and adhesion prevention. It also specializes in intensive care unit (ICU) treatments like continuous renal replacement and other organ support therapies. The company's portfolio extends to integrated connected care solutions, featuring advanced devices, software, communication tools, and integration technologies. Furthermore, Baxter delivers comprehensive patient monitoring and diagnostic tools for detecting, treating, and managing a wide range of illnesses, including respiratory, cardiac, vision, and physical assessment needs, as well as providing specialized surgical suite equipment like video systems, operating tables, and precision positioning devices. Beyond its own products, Baxter offers contract manufacturing and development services to pharmaceutical and biopharmaceutical partners. These diverse products and services are utilized across numerous healthcare settings, from hospitals, kidney dialysis centers, nursing homes, and rehabilitation facilities to doctors' offices and directly by patients at home under medical supervision. Baxter markets its offerings in approximately 100 countries, leveraging a direct sales force, independent distributors, drug wholesalers, and specialized pharmacy or alternative site channels. Established in 1931 and headquartered in Deerfield, Illinois, the company also has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules.
Related entities
Subsidiaries (9)
Baxter AG
BAXTER HEALTHCARE LIMITED
Baxter Healthcare SA
BAXTER INNOVATIONS AND BUSINESS SOLUTIONS PRIVATE LIMITED
BAXTER PHARMACEUTICAL (ASIA) PTE. LTD.
BAXTER PHARMACEUTICALS INDIA PRIVATE LIMITED
BAXTER (MALTA) TRADING COMPANY LIMITED
Gambro Lundia AB
Key people
Heather Knight
Chief Operating Officer, Executive Vice President, Interim Group President, Medical Products and Therapies · since 2025
James Borzi
Executive Vice President and Chief Supply Chain Officer · since 2023
Joel Grade
Chief Financial Officer, Executive Vice President · since 2025
Jeanne Mason
Chief Human Resources Officer, Executive Vice President · since 2023
Reazur Rasul
Executive Vice President, Group President - Healthcare Systems and Technologies · since 2023
David Rosenbloom
Executive Vice President, General Counsel · since 2023
Alok Sonig
Executive Vice President, Group President - Pharmaceuticals · since 2023
Lead Independent Director · since 2025
D. Brent Shafer
Chairman of the Board, Interim Chief Executive Officer · since 2025
William Ampofo
Independent Director · since 2023
Independent Director · since 2024
Independent Director · since 2019
Independent Director · since 2019
Stephen Oesterle
Independent Director · since 2017
David Wilkes
Independent Director · since 2021
Legal address
C/O THE CORPORATION TRUST COMPANY
CORPORATION TRUST CENTER
1209 ORANGE ST
WILMINGTON, DE 19801
US
CORPORATION TRUST CENTER
1209 ORANGE ST
WILMINGTON, DE 19801
US
Headquarters
1 BAXTER PARKWAY
DEERFIELD, IL 60015
US
DEERFIELD, IL 60015
US
Trading name
BAXTER TRAVENOL LABORATORIES INC
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||